biostudies-literatureAmat-Bou MBarcelona Magic LineE3123https://www.ebi.ac.uk/biostudies/studies/S-EPMC7650793biostudies-literatureUnknown12(10)Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1's effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo-BPL1 (<i>n</i> = 19) or BPL1-placebo (<i>n</i> = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray abNutrientsEffects of <i>Bifidobacterium animalis</i> Subsp. <i>lactis</i> (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial.PMC7650793n.a.Garcia-Ribera SSanchez-Infantes DRamon-Krauel MAmat-Bou MLerin CPiquer-Garcia IElias MCorripio RRamon DCliment EJimenez-Chillaron JCChenoll EIbanez LVillalta LfalseEffects of <i>Bifidobacterium animalis</i> Subsp. <i>lactis</i> (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial.Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1's effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo-BPL1 (<i>n</i> = 19) or BPL1-placebo (<i>n</i> = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray ab2020-01-01T00:00:00Z2020 Oct2026-04-07T17:42:55.104Z2020-11-19T16:56:59ZS-EPMC76507933306610710.3390/nu12103123